Clinical trials: Stage II Adult Soft Tissue Sarcoma AJCC v7
Sarcoma
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00077285
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002791
- Testing
- filgrastim, dacarbazine, doxorubicin hydrochloride
- Where
- 237 sites in United States, Canada and 1 more
- Sponsor
- Radiation Therapy Oncology Group
Sarcoma
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00091351
- Testing
- conventional surgery, radiation therapy
- Where
- 59 sites in United States, Canada
- Volunteers
- 370 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Cervical Cancer
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective cancer treatment. PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen in tumor cells of patients who…
- Conditions
- Breast Cancer, Cervical Cancer, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT00004261
- Testing
- EF5, flow cytometry, fluorescent antibody technique
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing melphalan directly to the tumor may kill more tumor cells and cause less damage to healthy tissues.
- Conditions
- Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT00019968
- Testing
- melphalan, tumor necrosis factor
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphedema, Musculoskeletal Complications
Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
RATIONALE: Image-guided radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a lower dose of radiation directly to the tumor may kill more tumor cells and cause less damage to…
- Conditions
- Lymphedema, Musculoskeletal Complications, Radiation Fibrosis, Radiation Toxicity
- Trial name
- NCT00589121
- Testing
- Chemotherapy, Radiation therapy, Surgery
- Where
- 17 sites in United States, Canada
- Volunteers
- 98 people
- Sponsor
- Radiation Therapy Oncology Group
Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
This phase II trial is studying how well CCI-779 works in treating patients with soft tissue sarcoma or gastrointestinal stromal tumor.
- Conditions
- Gastrointestinal Stromal Tumor, Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma
- Trial name
- NCT00087074
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer
This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment
- Conditions
- Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Adult Soft Tissue Sarcoma, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00896961
- Testing
- EF5, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)